MarketPulse

cancer therapeutics

2 articles
The Motley FoolThe Motley Fool··Jake Lerch

Boxer Capital Doubles Down on TNGX With $9.5M Stake as Biotech Stock Soars

Boxer Capital invests $9.5M in clinical-stage biotech $TNGX, raising stake to 21.09%, as stock surges 427% amid Gilead partnership momentum.
GILDTNGXIBBbiotechclinical-stage
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Soleus Capital Elevates Celcuity to Third-Largest Position With Major Share Purchase

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.
PRAXCELCKRYSNVCRportfolio allocationinstitutional buying